Literature DB >> 14624149

Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England.

Margaret A Stone1, John F Mayberry, Richard Baker.   

Abstract

OBJECTIVES: To estimate the prevalence of inflammatory bowel disease (IBD) from the information in general practitioners' records and to describe patient management, including the prescribing of 5-aminosalicylates and adherance to treatment in ulcerative colitis, and frequency of advice given concerning cessation of smoking.
METHODS: Fifteen general practices were recruited through the Trent Focus Collaborative Research Network, UK, to take part in a cross-sectional study. They identified confirmed cases of IBD and used a pro-forma to collect data for collation and analysis.
RESULTS: Searches identified 344 IBD cases from a combined list of 86 801 patients, suggesting a prevalence of 396 per 100 000 (95% confidence interval, 356-440). Practices considered 32% of patients to be under the sole care of general practitioners; only 59% had been seen in secondary care during the previous year and the numbers of outpatient and general practitioner consultations were similar. Smoking cessation advice was documented for similar numbers of smokers with Crohn's disease and ulcerative colitis. Excluding patients who had undergone surgery, only 65% of patients with ulcerative colitis had been prescribed a 5-aminosalicylate in the previous 6 months and good treatment adherence was suggested in only 42% of ulcerative colitis patients taking a 5-aminosalicylate. Prescribing of aminosalicylates was more common in patients under specialist or shared care than those under general practitioner care only; this remained significant in a regression model also including extent of disease (P < 0.0001).
CONCLUSIONS: General practitioners play an important role in caring for patients with IBD and may need relevant education and support. Aminosalicylates appear to be under-used in patients with ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624149     DOI: 10.1097/00042737-200312000-00004

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  42 in total

Review 1.  Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe?

Authors:  L Lakatos; P L Lakatos
Journal:  Postgrad Med J       Date:  2006-05       Impact factor: 2.401

Review 2.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

3.  Racial disparities in utilization of specialist care and medications in inflammatory bowel disease.

Authors:  Geoffrey C Nguyen; Thomas A LaVeist; Mary L Harris; Ming-Hsi Wang; Lisa W Datta; Steven R Brant
Journal:  Am J Gastroenterol       Date:  2010-05-18       Impact factor: 10.864

4.  Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis.

Authors:  Qi-Kui Chen; Shi-Zheng Yuan; Zhuo-Fu Wen; Ying-Qiang Zhong; Cu-Jun Li; Hui-Sheng Wu; Can-Rong Mai; Peng-Yan Xie; Yu-Min Lu; Zhong-Lin Yu
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

Review 5.  Is There a Link Between H. Pylori and the Epidemiology of Crohn's Disease?

Authors:  Ayesha Shah; Nicholas J Talley; Marjorie Walker; Natasha Koloski; Mark Morrison; Daniel Burger; Jane M Andrews; Michael McGuckin; Mike Jones; Gerald Holtmann
Journal:  Dig Dis Sci       Date:  2017-03-09       Impact factor: 3.199

Review 6.  Autophagy and Crohn's disease: at the crossroads of infection, inflammation, immunity, and cancer.

Authors:  P Brest; E A Corcelle; A Cesaro; A Chargui; A Belaïd; D J Klionsky; V Vouret-Craviari; X Hebuterne; P Hofman; B Mograbi
Journal:  Curr Mol Med       Date:  2010-07       Impact factor: 2.222

7.  Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study.

Authors:  Carolynne J Vaizey; Peter R Gibson; Christopher M Black; Rebecca J Nicholls; Adèle R Weston; Daniel R Gaya; Shaji Sebastian; Ian Shaw; Stephen Lewis; Stuart Bloom; John N Gordon; Amanda Beale; Ian Arnott; Simon Campbell; Tao Fan
Journal:  Frontline Gastroenterol       Date:  2014-01-24

8.  A dedicated inflammatory bowel disease service quantitatively and qualitatively improves outcomes in less than 18 months: a prospective cohort study in a large metropolitan centre.

Authors:  Vinh-An Huu Phan; Daniel R van Langenberg; Rachel Grafton; Jane M Andrews
Journal:  Frontline Gastroenterol       Date:  2012-05-01

Review 9.  Tools for primary care management of inflammatory bowel disease: do they exist?

Authors:  Alice L Bennett; Pia Munkholm; Jane M Andrews
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 10.  Strategies to improve adherence and outcomes in patients with ulcerative colitis.

Authors:  Sunanda V Kane
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.